Copyportfolio CRISPR-Tech: eToro's formula to invest in biotechnology

Promoted

The acronym CRISPR comes from Clustered Regularly Interspaced Short Palindromic Repeats. This technology is revolutionising the biotechnology sector and from now on it will also revolutionise the wallets of many investors.

A recent breakthrough in DNA editing called CRISPR-Cas9 has advanced the field of biological technology by leaps and bounds. It is now technically possible to do nearly anything imaginable with our cells and to create new variations of animals and human beings.. The CRISPR are families of DNA sequences in bacterias, these fragments are used by bacteria to detect and destroy DNA in new attacks by similar viruses, and therefore be more efficient defending themselves from them. It’s currently being used for the editing of genes in which a sequence is added, eliminated or modified and also in the genetic regulation in several species.

eToro has created a revolutionary product as part of its Copyportfolios which can give investors exposure to this new innovative technoolgy. eToro’s CRISPR-Tech copyfund brings together some of the stocks of the most promising companies who are using this new technology CRISPR. It contains great A-list companies with an accumulated market capitalization of over 300,000 million dollars. And small capitalization biotechnology campaigns (with a market limit of 1bn dollars or less), each one with the potential of positively impacting in the future of the life sciences.

The selection of every CRISPR Copyportfolio company is assigned in equal parts and it’s re-adjusted periodically. Some of the main companies of the CRISPR Copyportfolio are:

- Editas Medicine is a US company that clinically tests the CRISPR technology to try on a rare disease known as Leber’s congenital amaurosis, a genetic illness that produces blindness.

- Agilent Technologies is an old division of HP that is centered in developing software and analytical instruments for labs all around the world. It carries out a main roll in the CRISPR technology sector.

- Sangamo Therapeutics counts with 20 years of experience in genetic therapeutics. It works on different treatments for different illnesses. For example it investigates a genetic therapy for the people who are immune to HIV.

- Merck, the third biggest global medicines manufacturer, is also very involved in the CRISPR technology sector. It has developed a set of tools for genetic editing like “DNA scissors”, that allow to cut and replace segments of DNA.

- Cellectis is a French company that employs the genetics editing technology to develop treatments to fight cancer. Their technology uses CRISPR to modify the T cells of healthy donors so that the receiving body doesn’t reject them.

The users of eToro can now invest in Copyportfolio CRISPR if they register in the platform. The community sums up more than 6 million members and this wallet of biotechnological companies has become in a short space of time one of the most followed. Also, thanks to the Copyportfolios technology, the investors won’t have to do anything because the platform is in charge of managing the wallets and of monthly rebalancing the invested capital in case each value needs to be underweight or overweight.

As if that was not enough, the new eToro users have a virtual wallet of 100,000 dollars with which they can test all their investment strategies or other user’s strategies, thanks to a function in the platform that enables them to clone other members wallets.

*Cryptocurrencies can fluctuate widely in prices and are therefore not appropriate for all investors. Trading cryptocurrencies is not supervised by any EU regulatory framework. Past performance does not guarantee future results. Trading history presented is less than 5 years and may not suffice as basis for investment decision. Your capital is at risk.